Markets Maxim ups AIM ImmunoTech PT to $5 from $2 Maxim Group raised its price target for AIM ImmunoTech (NYSE American:AIM) to $5 from $2, citing a strengthened balance sheet and a $14.54-million award from the NCI to study its Ampligen drug candidate in up to five... April 6, 2020